RTP Mobile Logo

Friday, May 18, 2018, Washington, DC, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A CNE Symposia Series Held During the 43rd Annual ONS Congress

PART 5 — Acute Leukemias

Event Details

Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Bernadette Cuello, MSN, NP-C, AOCNP
Nurse Practitioner, Outpatient Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M Stein, MD
Hematologist and Medical Oncologist
Assistant Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Wendy Stock, MD
Anjuli Seth Nayak Professor of Leukemia Research
Director, Leukemia Program
The University of Chicago Medicine
Chicago, Illinois

Lauren Ziskind, APN, NP-C, OCN
Nurse Practitioner, Adult Leukemia Program
The University of Chicago
Chicago, Illinois

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celgene Corporation and Jazz Pharmaceuticals Inc during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Module 1: Acute Myeloid Leukemia (AML)


  • Evaluation of cytogenetic and molecular abnormalities in patients with AML
  • Data supporting the FDA approval of enasidenib for patients with relapsed or refractory AML and an IDH2 mutation
  • Common side effects associated with enasidenib; monitoring for differentiation syndrome and other adverse events
  • Similarities and differences between IDH2 and IDH1 mutations; available data with the IDH1 inhibitor ivosidenib
  • FDA approval of midostaurin for patients with newly diagnosed AML and a FLT3 mutation; patient selection and practical aspects related to its administration
  • Incidence and severity of side effects associated with the use of midostaurin in younger and older patients in the induction and maintenance settings
  • Ongoing evaluation of novel FLT3 inhibitors (eg, gilteritinib, quizartinib) in AML
  • Comparative efficacy and toxicity profiles observed with midostaurin, gilteritinib and quizartinib
  • Current clinical role of gemtuzumab ozogamicin for CD33-positive AML
  • Indications for the use of hypomethylating agents as induction and/or maintenance therapy in elderly, transplant-ineligible patients or those with poor-risk AML
  • Dose adjustment strategies for older patients with AML receiving azacitidine or decitabine
  • Incidence of Bcl-2 overexpression in patients with AML; correlation between Bcl-2 expression and response to venetoclax
  • Dosing of venetoclax in patients with AML; side effects and toxicities observed in clinical trials to date and comparison to those seen in patients with chronic lymphocytic leukemia receiving this drug
  • Defining therapy-related AML and AML with myelodysplasia-related changes
  • Formulation of CPX-351 and effect on efficacy and tolerability compared to standard induction therapy
  • Unique considerations regarding the preparation and handling of CPX-351; potential ramifications of not following outlined requirements to appropriately reconstitute and administer the drug

Module 2: Acute Lymphocytic Leukemia (ALL)


  • Selection of first-line therapy for younger and older patients with Philadelphia chromosome-negative ALL
  • Incorporation of pediatric-like regimens into treatment for young adult and adult patients
  • Mechanism of action of blinatumomab, clinical trial data leading to its FDA approval and incorporation into nonresearch treatment algorithms
  • Counseling patients about to receive blinatumomab regarding recommended hospitalization
  • Incidence and management of cytokine release syndrome and neurological toxicities associated with blinatumomab
  • Biologic rationale for targeting CD22 with inotuzumab ozogamicin in ALL and data sets leading to its FDA approval
  • Frequency of adverse events with inotuzumab ozogamicin, including delayed platelet recovery and veno-occlusive disease
  • FDA approval of chimeric antigen receptor (CAR) T-cell therapy for pediatric and young adult patients with ALL that is refractory or in second or later relapse
  • Persistence and durability of responses with CAR T-cell therapy
  • Frequency of cytokine release syndrome and neurologic toxicities in patients undergoing treatment with CAR T-cell therapy and possible preventive strategies

CE Information

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute leukemias.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with acute myelogenous leukemia (AML).
  • Develop an understanding of the mechanism of action, available data and current and potential role of available and investigational IDH1/2 inhibitors for patients with relapsed/refractory AML and IDH1/2 mutations.
  • Recognize the recent FDA approval of CPX-351 for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be optimally integrated into nonresearch care algorithms for these patients.
  • Apply the results of clinical research on existing (CAR-T therapy, blinatumomab, inotuzumab ozogamicin) and emerging agents to optimize the clinical and supportive care of patients with newly diagnosed and recurrent acute lymphocytic leukemia.
  • Educate patients about the side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2018/ILNA

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP staff and external reviewers — The scientific staff, planners and managers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celgene Corporation and Jazz Pharmaceuticals Inc.


Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room: 
Independence A-E (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and provides direct access to the Walter E Washington Convention Center via an underground concourse.



Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 5 — Acute Leukemias. Onsite registration will be open starting at 5:30 AM (ET) on Friday, May 18th.

If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside Independence A-E, Ballroom (Meeting Level 4) at the Marriott Marquis Washington, DC (901 Massachusetts Ave NW, Washington, DC 20001). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.